Santa Cruz Biotechnology

c-Abl (24-11) | Santa Cruz Biotechnology

mouse monoclonal IgG1; c-Abl Antibody (24-11) is an IgG1 mouse monoclonal c-Abl antibody (also designated c-Abl antibody or ABL1 antibody) that detects c-Abl p120 and chimeric Bcr/Abl proteins in CML and ALL of mouse, rat and human origin by WB, IP, IF and ELISA. c-Abl Antibody (24-11) is available as the non-conjugated anti-c-Abl antibody form. The Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. In these leukemias the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing the Philadelphia (Ph1) chromosome. The molecular consequence of this trans-location is the generation of a chimeric Bcr/c-Abl mRNA encoding activated Abl protein-tyrosine kinase. The Bcr gene has been shown to encode a GTPase-activating protein (GAP) specific for the Ras-related GTP-binding protein, p21rac.

Reviews


No reviews yet

ABOUT THE COMPANY

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research antibodies, siRNA and CRISPR Gene editing tools, biochemicals, labware and more recently has expanded into animal health care products. Santa Cruz Biotechnology has the highest commitment to quality and customer service.